Ellen Lentz
Nurse Practitioner · Wasilla, AKNPI 1306949193
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 26.3% of the total. Reporting peaked in 2024 at $1,231 and has fallen 53.5% since, to $573 in 2025. Among nurse practitioner clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$578
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$357
- Nestle Healthcare Nutrition Inc.$286
- Novo Nordisk$254
- GSK$238
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,49599%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $1,199 |
| AstraZeneca | 24 | $578 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $357 |
| Nestle Healthcare Nutrition Inc. | 13 | $286 |
| Novo Nordisk | 13 | $254 |
| GSK | 8 | $238 |
| Aimmune Therapeutics, Inc. | 8 | $199 |
| Pfizer | 10 | $189 |
| Axsome Therapeutics, Inc. | 7 | $168 |
| Exact Sciences | 7 | $165 |
| Amgen | 3 | $155 |
| Abbott | 1 | $132 |
| Merck | 5 | $79 |
| Biohaven Pharmaceuticals, Inc. | 4 | $63 |
| Insmed, Inc. | 1 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Eisai Inc. | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Nevro Corp. | 1 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Corium, LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Digestive Care, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,562 in reported general payments places this provider in the 95th percentile of 212 nurse practitioner providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $132,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $30,951 |
| JanuviaSitagliptin Phosphate | 20 | $24,526 |
| FarxigaDapagliflozin Propanediol | 26 | $23,876 |
| MyrbetriqMirabegron | 11 | $10,288 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $8,463 |
| Estradiol | 32 | $5,092 |
| Armour ThyroidThyroid,pork | 36 | $3,599 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $2,821 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 76 | $2,586 |
| SynthroidLevothyroxine Sodium | 23 | $2,482 |
| Omega-3 Acid Ethyl Esters | 12 | $1,595 |
| Levothyroxine Sodium | 140 | $1,521 |
| Gabapentin | 85 | $1,408 |
| Np ThyroidThyroid,pork | 13 | $1,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $254 | $132,31799 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $238 | $39,41541 claims |
| MerckJanuvia | $79 | $24,52620 claims |
| AstraZenecaFarxiga | $578 | $23,87626 claims |
| AbbVieArmour Thyroid, Synthroid | $1,199 | $6,08159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 212 nurse practitioner providers in Alaska.
Other nurse practitioner in Wasilla
- Tamara SimpsonWasilla$18K
- Charlotte NelsonWasilla$6K
- Samantha HamiltonWasilla$4K
- Helen SharpWasilla$1K
- Danielle CarlsonWasilla$1K
- Patricia PayneWasilla$478
- Erin RockeyWasilla$384
- Amanda WeidmanWasilla$245
- Jessica BrayPalmer$5K
- Amanda EnosPalmer$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.